Schizophrenia SAPHRIS is indicated for the treatment of schizophrenia in adults. The efficacy of SAPHRIS was established in two 6-week trials and one maintenance trial in adults Bipolar Disorder Monotherapy: SAPHRIS is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Efficacy was established in two 3-week monotherapy trials in adults Adjunctive Therapy: SAPHRIS is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Efficacy was established in one 3-week adjunctive trial in adults.